BACKGROUND: Little is known about treatment aims during the last 3 months of life. AIM: To investigate important treatment aims in the last 3 months of patients' lives in cases of non-sudden death. DESIGN AND SETTING: Mortality follow-back study in The Netherlands. METHOD: Data were collected retrospectively in 2009 within the representative Sentinel Network of GPs in The Netherlands. GPs completed a standardised registration form. RESULTS: Data for 279 patients were studied. Of these, 55% died of cancer and 45% of another disease. Treatment was aimed at palliation for 73% of the patients in months 2 and 3 before death, and for 95% of the patients in the last week of life. Seven per cent received treatment aimed at cure in the last week of life. In a minority of patients, cure/life prolongation and palliation were simultaneously important treatment aims. In the last week of life and in the 2-4 weeks before death, cure was more frequently reported as an important treatment aim in patients with a non-cancer disease than in patients with cancer. In the 2-4 weeks before death, palliation was an important treatment aim for a larger proportion of patients with cancer than patients with other diseases. CONCLUSION: Registration by GPs show that, in the last weeks and days of life, cure was more frequently reported as an important treatment aim in patients with a non-cancer disease than in patients with cancer. For a small number of patients, palliation and cure/life prolongation were simultaneously important treatment aims.
BACKGROUND: Little is known about treatment aims during the last 3 months of life. AIM: To investigate important treatment aims in the last 3 months of patients' lives in cases of non-sudden death. DESIGN AND SETTING: Mortality follow-back study in The Netherlands. METHOD: Data were collected retrospectively in 2009 within the representative Sentinel Network of GPs in The Netherlands. GPs completed a standardised registration form. RESULTS: Data for 279 patients were studied. Of these, 55% died of cancer and 45% of another disease. Treatment was aimed at palliation for 73% of the patients in months 2 and 3 before death, and for 95% of the patients in the last week of life. Seven per cent received treatment aimed at cure in the last week of life. In a minority of patients, cure/life prolongation and palliation were simultaneously important treatment aims. In the last week of life and in the 2-4 weeks before death, cure was more frequently reported as an important treatment aim in patients with a non-cancer disease than in patients with cancer. In the 2-4 weeks before death, palliation was an important treatment aim for a larger proportion of patients with cancer than patients with other diseases. CONCLUSION: Registration by GPs show that, in the last weeks and days of life, cure was more frequently reported as an important treatment aim in patients with a non-cancer disease than in patients with cancer. For a small number of patients, palliation and cure/life prolongation were simultaneously important treatment aims.
Authors: Sander D Borgsteede; Corrie Graafland-Riedstra; Luc Deliens; Anneke L Francke; Jacques Thm van Eijk; Dick L Willems Journal: Br J Gen Pract Date: 2006-01 Impact factor: 5.386
Authors: Sander D Borgsteede; Luc Deliens; Corrie Graafland-Riedstra; Anneke L Francke; Gerrit van der Wal; Dick L Willems Journal: Patient Educ Couns Date: 2006-12-08
Authors: Sander D Borgsteede; Luc Deliens; Anneke L Francke; Wim A B Stalman; Dick L Willems; Jacques T M van Eijk; Gerrit van der Wal Journal: Palliat Med Date: 2006-03 Impact factor: 4.762
Authors: D Fitzsimons; D Mullan; J S Wilson; B Conway; B Corcoran; M Dempster; J Gamble; C Stewart; S Rafferty; M McMahon; J MacMahon; P Mulholland; P Stockdale; E Chew; L Hanna; J Brown; G Ferguson; D Fogarty Journal: Palliat Med Date: 2007-06 Impact factor: 4.762
Authors: Sander D Borgsteede; Luc Deliens; Barry Beentjes; François Schellevis; Wim A B Stalman; Jacques Th M Van Eijk; Gerrit Van der Wal Journal: Palliat Med Date: 2007-07 Impact factor: 4.762
Authors: Sander D Borgsteede; Luc Deliens; Gerrit van der Wal; Anneke L Francke; Wim A B Stalman; Jacques T M van Eijk Journal: Scand J Prim Health Care Date: 2007-12 Impact factor: 2.581
Authors: Hilary Pinnock; Marilyn Kendall; Scott A Murray; Allison Worth; Pamela Levack; Mike Porter; William MacNee; Aziz Sheikh Journal: BMJ Date: 2011-01-24
Authors: Kim Beernaert; Luc Deliens; Koen Pardon; Lieve Van den Block; Dirk Devroey; Kenneth Chambaere; Joachim Cohen Journal: PLoS One Date: 2015-09-10 Impact factor: 3.240
Authors: Maria Sercu; Veerle Van Renterghem; Peter Pype; Karolien Aelbrecht; Anselme Derese; Myriam Deveugele Journal: Scand J Prim Health Care Date: 2015-12-10 Impact factor: 2.581